维普资讯 doc.guandang.net
Re om bi a thum an i t I Uk n 1 ort e t en f c n n n ere i一 1 f r a m to c em o h a y i du e h om b c t e a i a i n s h t er p -n c d t r o y op ni n p te t w ih g s r i t s i a a c t a t o e t c er n n l n T iLnS e, n L, io o gZ a g J nL,i n n, e De g i L, i h n Ya iX a d n h n,i iJ a gGo g W i n e a f
D p r n at itsn l n o g, e ig nv r t h o o n oo y B in a cr si l e at t f s onet a O c l y P kn ies yS o l f clg, e ig n e pt& me o G r i o U i c O j C Ho a Is tt, e n 0 3, hn n tueB j g1 0 6 C ia i i 0 R c i d 6 M y2 0 R vs d 1 u e2 0 A c pe: 9J n 0 7 e ev: a 0 7/ e i: J n 0 7/ c e t d 2 u e2 0 e e 5
A src O j te T vl t t f c n a t o cm i n h m nieek .1( l 1)0 t hm - bt t be i:oea a eei yadsfy feo b at u a trui1 r L f ece o a cv ue h f a C e r n n l n h - 1 rh t ea y i u dt rmb c tp nai p t nsw t g sr i e t a c n rMeh d:t sa p n d a dn nr n o z d h r p . d c o o yo e i n ai t i a t n si l a c . t o s I n e h e h o t n e no e e n o - d mi wa a e c nrldcic ltd. e h lee o nswa n e 5x10Latr h moh rp,hL1 a d n trd2 o t l li u y Wh ntep tl c u t oe na s a t su d r 0/ f e te y rI-1w sa miiee 5 7 ec a s
p/g ) s ay Cietnato 1 aso iot udw e le to n 10 0/. e us Svn . g k a di j i sf
7 4 y,r s nne h n a l ut O 10 R s l: eet ( d a lS n co I r— d dc i p te c s x L t y s ainsw r n o e t i su y T et a me t r u n ec nr I r u a i -ih s s rs e t e . h i p t t e ee r l di ot s t d . h e t n o pa dt o t o ph dt r eg t e .e p ci l T e x e l n h r g h o g h t y a c vy
m a cvr t etP T 10 0/w s .dy ete tru, hen o tIru a .dy ( en eoeyi L 0 10 a 1 asnr m ng pw i lcn o p s 22 asP<0 1. r m o x L 8 ila o l rg o w 1 .) 0 Moe v rteme nrc v r me仃 m L r o e,h a o eyt e i 0 P T≤5 0『 t 1 0x 1 0Lw s89 d y e t n ru . i o t I 0 x 1 0L o 0 0/ a . a si t ame t o p whl i c n r nr g en o
q u a .dy ( 0 5.hrw s aii Ii r c tenh o rusM j d eti l e e a r p s 9 asP< . ) e a s tt f ee b w e e op. a ri e c c dd d m, o w 1 2 0 T e a t sc df n e a e t t g w os e f sn u e fv ra t u r s l s r n s . u e r l l a dw ltlrbe C n lso,r I-1c nb aeya de e t e e e, rc l c o e e s b t yweeaI d n eIoe l. o cu i, hL 1 a es f l n f c v l i a mu e h t mi a: i y
u e r et ame t f h moh rp - d c dtrmb ctp n ainswf a t ie t a c n r sdf e t n e tea yi u o o y e ij p t t i g sr n sn l c . ot r h oc n e h o an e h o t i e a
K y od r o b at u a tl k - ( l 1)gs ietacn rho bctpn;hm t r y e rs e m i n hm nn rui1 r L:at n
sn l c; r oy ei ce o e p w c n iee n h 1 1 o r t i e t m a o a ha
S v r t o bo y o ni a t r he o he a y e e e hr m c t pe a fe c m t r p m a c nc r a i r c nc r y a e nd l ve a e .Ea t r Co pe a i e Onc l g se n o r tv oo y l a o he o r a i e de y a r a m e td ly. e d t m r h gc t n nc nd te t n e a The Gr u E OG1 e f r a c tt s o p( C r o m n esa r o2 p l a i e p u we e0 t, al t i v he t e a y w s a pt d c r n o t to l t a iina r am e o hr m b c o e a i n r v— c m o h r p a do e .A c o di g t he N ai na r d to lte t nt f r t o o yt p ni s i t a e n usp a ee n uso w hih m a o k t m p a iy a d o l tl ti f in, c y w r e orrl n i m u l g c 1r a ton, n nc e s he c nc fi m no o ia e c i a d i r a e t ha e o n— aki d o yt k new hih o db e o p a ee e r - n fc o i c c nt ut st l tl tg ne a to a d ha e r po e wih ci c le c c t m e i n, n s be n e r d t lnia f a ya t i ho a da o d n br a .Thi e e r h am e to e v n h r a— sr s a c i d a bs r i g t e te t
C n e s tt o a crI f eC mmo o i t r ei NC— T ) ni u nT xc y C i r i t a( I C, C t rmb c t p na t rd r e e o r (b ou e h o o y o e i o ga e 2 o v n lwe a sl t g o s he te t e t g o p w a do e e ombi a t r up:t r a m n r u s a pt d r c n n
m a o sbl nd e p ae e nt d nd h
y p s i y i uc lt lta i bo y a om o e o t e pai n s w ho d v lpe c m o he a y i d e g ne us h te t e eo d he t r p—n uc d
fc o . e o ie u nitr u n 1 r I一1 i pae t o nss7× 1 L weesp rtdit wo et n R c mbn dh ma el k一 hL 1) s i n ei 1( l l u t 5 te c 0/) r e aa ot e n h ma tr u i一1( I一 1, n ec nrl ru u n i el kn 1 r L 1) a dt o to go p n e h h w a b e v to I s o— e ta, pe no r n m— so s r a i n.ti m no c n r lo n, n—a do a
s m p me t f c c f h o ma er I一 Jh l ) nc e ie, ndpa all dc n r l t d I o a i n o a int n i a yo eh me d L 1 u ei o h— z d a r lee o t o u y.nf r to f te s e t h 1(
mo h r p i uc d hr mbo y o ni n pai n sw t t e a y—nd e t o c t pe a i te t h w e es m m a ie n Ta e 1 i r u rz d i bl . g sr i e tna a e . a to ntsi lc nc r
Ma eral nd m e h ds t i sa t o Cl i a a era s i c I n m t i l AU h a int n l d i hi t d a e o t e p te si vove n t ss y h d be n c n— u
I es d, h L 1 J h l, n fcu e yS a— nt y r I一 u ei ma u a t rdb h n h t u 1( ̄ d n l P a ae t aC mpn, hn ) sd ns o g 3u h r cui l o a y C iawa mii 0 m c a— t tdsb ua e ul n e a ya a oe f 5 g(g ) r e c tn o s o c i d s / a u y d l t o2 p k d o o 1 y, rd s o i ue e hep a ee u s f r7t 4da s o ic ntn d w h n t lt l t o
nt c
0 1 9 L.Plt l t ta f i n wa lo d wh n a ee r nsuso s al we e im d it l g c l a v nc d un e e t b e o e ur n ≥ 1 0 x 0/ fr e h so o ial d a e r s c a l rr c re t y p a ee s c un ss 3× 1 L o morha i e e c l t lt o t 0 0/ r he r g c t nd n y a ea t tc g sr i e tn lc nc r ncu ng g src nd m t sai a to nt si a a e,i l di a ti c nc r o o e t lc nc r s ph g a a e,p n r a i a e,c l r ca a e,e o a e lc nc r a c e tc
e s d G a uo yecln t l ig f tr(— S ) i e x t . rn lc t—oo y s mua n a o G C F i t c w a d i se e fp te sd v lpe e e eluc p ni sa m nit r d i a int e e o d s v r e o e a o e to ni, ut rn u r pe a b GM— Fw a o e it d CS sn tp r te . m
C r sodnet J i m ile so r. or pne c:iL E a:j@cc.g n e o e . li i o c
doc.guandang.net
mg/dl days of treatment (circle 0) Michael S....of chemotherapy completion, Continued for at least...Induced by Recombinant Human Interleukin-11: ...
Recombinant human interleukin-1 1 for the treatment of chronic idiopathic ...3 .讨论 bocytopenia clue to chemotherapy〔J〕.Blood,1996,87(9): 3607—...
recombinant human interleukin 1 1(rhI L一1 1)de— rivative in the treatment of thrombocytopenia induced by Chemotherapy.Methods 20 tumor patients with ...
Effects of recombinant human interleukin-11 on LPS-induced intestinal ...rhIL-11 (100 ng/mL) was administered following LPS treatment and these ...
Interleukin-11 for Treatment of Hepatitis ...of chemotherapy completion, Continued for at least...Induced by Recombinant Human Interleukin-11: ...
mg/dl days of treatment (circle 0) Michael S....(环磷酰胺) Campath-1H Combination chemotherapy(联合...Induced by Recombinant Human Interleukin-11: ...
(Combination chemotherapy) 霉酚酸酯(Mycophenolate ...A, treatment with rhIL-11 reduced the ...Induced by Recombinant Human Interleukin-11: ...
of chemotherapy-induced thrombocytopenia resulted ...Treatment plan Patients were to receive at least ...Effects of recombinant human interleukin-11 on ...
g/kg mg/dl days of treatment (circle 0) ) ...in Women With Breast Cancer Receiving Chemotherapy....Induced by Recombinant Human Interleukin-11: ...
Recombinant human bone... 暂无评价 5页 1下载...c Of?cer, Interleukin Genetics, Waltham, MA. ?...Treatment of moderate to severe periodontitis suf?...
热门文档